Friday, October 7, 2016

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Celgene (CELG) and Chubb (CB).

Shares of Strong Buy rated Amazon have been strong performers lately (they are up more than 25% year-to-date), with analysts steadily raising estimates for this year and next. The analyst likes the manner in which Amazon is driving value across all its businesses despite the super-competitive nature of the retail business. With a number of major brick-and-mortar operators like Wal-Mart and others making concerted efforts in the online arena, Amazon has been able to capitalize on the secular growth in ecommerce with the help of not only choice and convenience but also prices. Also, the AWS generates much higher margins than retail, so it has a very positive impact on Amazon’s profitability. The company has a solid loyalty system in Prime and its FBA strategy, and content addition continues to add selection to Prime memberships. (You can read the full research report on Amazon here>>)

Celgene shares have been laggards this year, in line with the broader pharmaceutical space, reflecting political uncertainty around pricing issues. But the analyst likes buy-rated Celgene’s key growth driver, Revlimid, which continues to benefit from market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – should continue to drive the top line. The company’s raised outlook for 2016 is also encouraging. Meanwhile, label expansion of approved drugs would boost its revenues. Celgene’s pipeline also looks interesting with several data readouts expected in the second half of the year, and over the next few years. (You can read the full research report on Celgene here>>)

Chubb shares are up today, but they have struggled this year on broad macro issue notwithstanding, the analyst likes Chubb’s complementary products and services and its inorganic growth story. A strong capital position helps Chubb to engage in shareholder friendly moves and invest in strategic initiatives that drive growth. Recently, Chubb announced that its enterprise-wide insurance solution, Integrity+, will now be available in Canada. The latest policy will protect Canadian companies from errors and omissions (E&O) liability customer lawsuits.  (You can read the full research report on Chubb here>>)

Other noteworthy reports we are featuring today include Monsanto (MON), Delta (DAL) and Merck (MRK).

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for October, 2016 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>

You can find all of today's stock research reports here>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>